Serlopitant

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Serlopitant
Serlopitant structure.png
Systematic (IUPAC) name
3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)-octahydro-2H-isoindol-2-yl]cyclopent-2-en-1-one
Clinical data
Routes of
administration
Oral
Identifiers
CAS Number 860642-69-9
ATC code none
PubChem CID: 23653789
ChemSpider 24686685
UNII 277V92K32B YesY
KEGG D09378
ChEMBL CHEMBL447955
Chemical data
Formula C29H28F7NO2
Molecular mass 555.527 g/mol
  • C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2CC[C@@H]3CN(C[C@H]3[C@@H]2C4=CC=C(C=C4)F)C5=CC(=O)CC5
  • InChI=1S/C29H28F7NO2/c1-16(19-10-20(28(31,32)33)12-21(11-19)29(34,35)36)39-26-9-4-18-14-37(23-7-8-24(38)13-23)15-25(18)27(26)17-2-5-22(30)6-3-17/h2-3,5-6,10-13,16,18,25-27H,4,7-9,14-15H2,1H3/t16-,18-,25-,26+,27+/m1/s1
  • Key:FLNYCRJBCNNHRH-OIYLJQICSA-N

Serlopitant (VPD-737) is a drug which acts as an NK1 receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development.[1][2]

See also

References

  1. Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol. 2010 Aug;184(2):616-22. doi: 10.1016/j.juro.2010.03.147 PMID 20639026
  2. Payton S. Urinary incontinence: Neurokinin receptor antagonist inferior to tolterodine for OAB. Nature Reviews Urology 2010; 7:418. doi:10.1038/nrurol.2010.105



<templatestyles src="Asbox/styles.css"></templatestyles>